The association of complement C3 expression with breast cancer primary tumor and lymph node metastatic breast cancer has been documented by Popeda et al., pointing toward targeting C3 for therapeutic purposes (Popeda et al., 2021). The gene discussed is C3; the disease is breast carcinoma.